Hummingbird Bioscience Licenses Monoclonal Antibodies To Immunome For Exclusive Worldwide Use, Receives Upfront Payment And Potential Milestone Payments, Royalties
Hummingbird Bioscience Licenses Monoclonal Antibodies To Immunome For Exclusive Worldwide Use, Receives Upfront Payment And Potential Milestone Payments, Royalties
Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target.
Hummingbird Bioscience是一家精準生物治療公司，致力於發現和開發用於難治疾病的變革性生物製品，今天宣佈已向Immunome, Inc.（納斯達克：IMNM）授予獨家全球許可，該公司專注於開發首創和最優質的靶向癌症療法的生物技術公司，針對一個未公開的單一靶點的單克隆抗體。
Under the terms of the license agreement, Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Hummingbird Bioscience will receive an upfront payment and will be eligible for future development and commercial milestone payments, as well as royalties.
根據許可協議的條款，Immunome將負責結合這些抗體的產品的研究、開發、製造和商業化。Hummingbird Bioscience將獲得預付款，並有資格獲得未來開發和商業里程碑付款，以及版權費用。
